Market Research

Psychedelic Invest is your source for the latest business and investing news about the burgeoning psychedelics industry.

PRO: Last Week in Review – Field Trip, Oregon, Psilocybin, and More

May 2 • 1 min read

In our latest episode, Adam Tubero digs into last week’s Field Trip news, Oregon’ legalization of psilocybin, and a breakdown of natural versus synthetic psilocybin.

PRO: A Deeper Dive Into Cybin (CYBN)

Apr 22 • 1 min read

In our latest episode, Adam Tubero digs into one of the more well-known Psychedelic biotech companies in the industry, Cybin (CYBN). Tune in as we take a closer look at Cybin’s financials, the development of CYB003 – which has the potential to effectively treat major depressive disorder (MDD) and alcohol use disorder (AUD) – and…

PRO: A Deeper Dive Into ATAI’s Strategic Partnership With IntelGenX

Apr 21 • 1 min read

In March, IntelGenx Technologies Corp. (IGX) announced that its wholly-owned subsidiary, IntelGenx Corp, has agreed to a strategic partnership with atai Life Sciences (ATAI), one of the industry’s largest clinical-stage biopharmaceutical companies aiming to transform the treatment of mental health disorders. In connection with this partnership, atai acquired ~25% of IntelGenx for approximately $12.3 million…

PRO: A Deeper Dive Into The Numinus + Novamind Merger

Apr 15 • 2 min read

Earlier this week, Numinus Wellness Inc. (NUMI) struck a deal to acquire Toronto-based Novamind (NM) for approximately $20.8 million, marking one the of largest mergers to date inside the public psychedelic sector. For the past couple of years, Novamind, which operates solely in the United States, has made significant advances toward establishing a stronghold in…

PRO: Comparing The Largest Psychedelic Companies Post Earnings

Apr 8 • 1 min read

Another year, another set of blockbuster year-end results from the three most talked about companies in psychedelics. Mind Medicine (MNMD), Compass Pathways (CMPS), and atai Life Sciences (ATAI) have all greatly benefited from 2021’s banner year. With a handful of successful funding rounds, strategic partnerships, and their continuous push for drug development, the “Big 3”…

Pages: 1234567891011121314151617181920212223242526272829303132333435363738394041424344454647484950515253